Clinical Trial Search

Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…

Primary: Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) — 4; 0; 0; 1 Participants

Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants

Primary: Pathological Complete Response — 3 participants

Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants

Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index

Primary: Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax — 933 Ng/mL

Primary: Response Assessment — 0; 0; 0; 0 Participants

Primary: 24 Week Progression Free Survival — 23 percentage of participants

Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109

Primary: 4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin — 25; 9; 27; 13…

Primary: Progression-free Survival (PFS) — 1.8 months

Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76

Primary: Best Response — 0; 7; 11; 11 participants

Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants

Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125

Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery

Primary: To Evaluate the Efficacy of the Treatment — 1.9 Months

Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months

Primary: Clinical Response Rate (PR+CR) — 0; 0 Participants

Primary: Safety/Toxicity — 0; 0 participants

Primary: Overall Survival (OS) — 20.5; 18.1 months — p=0.14

Primary: Overall Survival (OS) — 18.07; 14.09 Months — p=0.0020

Primary: Tumor Response Rate Following Zoledronic Acid (Zometa) — 12.5 percentage of responders

Primary: Progression-free Survival — 3.0; 3.4 months

Primary: Overall Survival (OS) — 20.4 months

Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants

Primary: 1-year Progression-free Survival — 44; 33 percentage of participants

Primary: Number of Participants With an Objective Response — 1; 0; 0; 0 Participants

Primary: Disease Control Rate (DCR) — 75 percentage of participants